Drug-maker Regeneron Pharmaceuticals announced on Monday it has started late stage human testing of an antibody treatment for COVID-19. It said the tests are designed to show the drug’s effectiveness in preventing and treating the disease. Regeneron is launching one of the drug trials jointly with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The company said the goal is to test the drug’s ability to prevent infections in persons who have had close contact with a COVID-19 patient. Regeneron said it hopes the late-stage drug trial will involve about 2,000 patients across the United States.
What is an antibody treatment?
a remedy to decrease body mass index
a treatment to increase heart and breathing rates
a remedy to increase running speed
a treatment to stimulate the immune system to attack infectious cells
About how many patients are involved with the late-stage drug trial?
1,000
2,000
100
200
The late-stage drug trial featured in this article will take place in the United States.
Europe
the United States
South America
Africa